Trial Profile
Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Acronyms CIAO
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Apr 2020 Primary endpoint (Change of CD8+ tumor infiltrating lymphocytes) has not been met, according to results published in the Clinical Cancer Research
- 08 Apr 2020 Results (data cutoff date: 8 Nov 2019) were published in the Clinical Cancer Research